LCZ696
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heart Failure With Reduced Ejection Fraction
Conditions
Heart Failure With Reduced Ejection Fraction
Trial Timeline
Nov 1, 2013 → Aug 1, 2014
NCT ID
NCT01922089About LCZ696
LCZ696 is a phase 2 stage product being developed by Novartis for Heart Failure With Reduced Ejection Fraction. The current trial status is completed. This product is registered under clinical trial identifier NCT01922089. Target conditions include Heart Failure With Reduced Ejection Fraction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02389933 | Pre-clinical | Completed |
| NCT03909295 | Phase 3 | Terminated |
| NCT02661217 | Approved | Completed |
| NCT02226120 | Phase 3 | Completed |
| NCT01922089 | Phase 2 | Completed |
| NCT01621633 | Phase 2 | Completed |
| NCT01593787 | Phase 3 | Completed |
| NCT00913653 | Phase 2 | Completed |
| NCT01569815 | Phase 1 | Completed |
Competing Products
20 competing products in Heart Failure With Reduced Ejection Fraction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |